Put Options

18 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$12.17 - $24.61 $1,217 - $2,461
100 New
100 $0
Q2 2023

Jul 18, 2023

SELL
$17.23 - $21.71 $51,690 - $65,130
-3,000 Reduced 71.43%
1,200 $12,000
Q1 2023

May 01, 2023

BUY
$18.08 - $24.55 $21,695 - $29,460
1,200 Added 40.0%
4,200 $31,000
Q4 2022

Feb 07, 2023

SELL
$20.4 - $24.73 $40,800 - $49,460
-2,000 Reduced 40.0%
3,000 $13,000
Q2 2022

Aug 04, 2022

BUY
$19.35 - $35.04 $96,750 - $175,200
5,000 New
5,000 $20,000
Q4 2021

Jan 18, 2022

SELL
$30.19 - $40.28 $196,235 - $261,820
-6,500 Closed
0 $0
Q3 2021

Oct 26, 2021

BUY
$29.09 - $45.68 $95,997 - $150,744
3,300 Added 103.13%
6,500 $7,000
Q1 2020

May 07, 2020

BUY
$21.5 - $54.2 $62,350 - $157,180
2,900 Added 966.67%
3,200 $26,000
Q4 2019

Feb 06, 2020

SELL
$34.54 - $44.87 $51,810 - $67,305
-1,500 Reduced 83.33%
300 $0
Q3 2019

Oct 28, 2019

SELL
$31.84 - $50.88 $229,248 - $366,336
-7,200 Reduced 80.0%
1,800 $16,000
Q2 2019

Aug 09, 2019

SELL
$42.0 - $59.29 $205,800 - $290,521
-4,900 Reduced 35.25%
9,000 $114,000
Q1 2019

May 10, 2019

BUY
$40.82 - $62.45 $355,134 - $543,315
8,700 Added 167.31%
13,900 $126,000
Q4 2018

Feb 05, 2019

BUY
$39.11 - $75.15 $27,377 - $52,605
700 Added 15.56%
5,200 $68,000
Q3 2018

Nov 07, 2018

SELL
$65.0 - $82.15 $175,500 - $221,805
-2,700 Reduced 37.5%
4,500 $20,000
Q2 2018

Aug 10, 2018

BUY
$27.2 - $74.35 $136,000 - $371,750
5,000 Added 227.27%
7,200 $0
Q1 2018

May 11, 2018

BUY
$24.05 - $37.5 $26,455 - $41,250
1,100 Added 100.0%
2,200 $5,000
Q4 2017

Jan 17, 2018

SELL
$26.0 - $34.6 $70,200 - $93,420
-2,700 Reduced 71.05%
1,100 $0
Q3 2017

Oct 17, 2017

BUY
$18.0 - $32.95 $68,400 - $125,210
3,800
3,800 $0

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $496M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.